Beijing Dabeinong Technology Group Co.Ltd(002385) : Announcement on the company’s continued use of its own idle funds to purchase low-risk financial products

Securities code: Beijing Dabeinong Technology Group Co.Ltd(002385) securities abbreviation: Beijing Dabeinong Technology Group Co.Ltd(002385) Announcement No.: 2022040

Beijing Dabeinong Technology Group Co.Ltd(002385)

Announcement on the company’s continued use of its own idle funds to purchase low-risk financial products

The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions.

On April 21, 2022, Beijing Dabeinong Technology Group Co.Ltd(002385) (hereinafter referred to as “the company”) held the 35th meeting of the 5th board of directors of the company, deliberated and adopted the proposal on the company’s continued use of its own idle funds to purchase low-risk financial products, as follows:

In order to improve the use efficiency of funds, make rational use of its own funds and obtain better return on investment, the company and its subsidiaries intend to continue to use its own idle funds of no more than RMB 3 billion to purchase low-risk property management products on the premise of ensuring the daily operation capital demand and capital safety. The service life is from the date of deliberation and approval of the company’s 2021 annual general meeting to the date of shareholders’ meeting in 2022, which is within the above limit, The funds can be used on a rolling basis, that is, the balance of funds used for the investment of low-risk financial products at any one time point shall not exceed RMB 3 billion, and the general meeting of shareholders shall be requested to authorize the group’s financial management center to exercise the investment decision-making power within the limited amount within this period. The details are as follows:

1、 Investment overview

1. Investment purpose

The 17th meeting of the 5th board of directors and the 2020 annual general meeting of shareholders of the company considered and approved the proposal on the company’s continued use of its own idle funds to purchase low-risk financial products, and agreed that the company could purchase low-risk financial products by using its own idle funds of no more than 3 billion yuan. The above financial management business operates normally, improves the capital efficiency of the group and achieves good results.

As the company must maintain a certain scale of working capital in its daily operation, in order to effectively improve the efficiency of this part of capital while ensuring liquidity, it is planned to continue to use its own idle capital of no more than RMB 3 billion to purchase low-risk financial products under the condition of ensuring capital security and not affecting its daily operation.

2. Investment quota

The company and its subsidiaries use their own idle funds of no more than RMB 3 billion to purchase low-risk financial products. Within the above limit, the funds can be used in a rolling manner, that is, the balance of funds used for investment in low-risk financial products at any one time shall not exceed RMB 3 billion.

3. Investment varieties

The company and its subsidiaries use idle funds to invest in short-term low-risk financial products within 12 months. The investment scope of entrusted wealth management includes structured deposits, low-risk wealth management products and money market funds issued by commercial banks. Funds are not used for securities investment directly or indirectly, and financial products with stocks and their derivatives as investment targets are not purchased.

4. Source of funds

The source of funds is the self owned idle funds of the company and all units of the group (including wholly-owned / controlled subsidiaries of the company).

5. Investment period

From the date of approval by the 2021 annual general meeting of shareholders to the date of holding the 2022 annual general meeting of shareholders. The investment period of a single financial product shall not exceed 12 months.

6. Authorization management

Due to the strong timeliness of financial institutions’ financial products, in order to improve the handling efficiency, the group’s financial management center is authorized to be responsible for the specific implementation, and the group’s financial management center is authorized to introduce different financial institutions providing low-risk financial products according to business needs.

The financial management center of the group is responsible for the analysis and evaluation of the income and risk of financial products of financial institutions, and is responsible for the selection of financial products of the above financial institutions, the determination of the amount, the signing of contracts and agreements and other related matters, as well as the approval and risk control. At the same time, during the period of financial management, we should have closer contact and communication with banks or other financial institutions, track the latest developments of financial products, and take timely preservation measures if we judge or find any adverse situation, so as to control the investment risk to the greatest extent and ensure the safety of the company’s funds.

2、 Investment risk and risk control measures

1. Investment risk

(1) Although financial products belong to low-risk investment varieties, the financial market is greatly affected by macro-economy, and it is not ruled out that the investment is affected by market fluctuations;

(2) The company will intervene timely and appropriately according to the economic situation and changes in the financial market, so the actual return of investment is unpredictable.

2. Risk control measures to be taken

(1) The company will strictly abide by the principle of prudent investment and choose low-risk investment varieties. Do not use the funds directly or indirectly for securities investment, and do not buy financial products with stocks and their derivatives as the investment object. (2) The financial management center of the group will timely analyze and track the investment direction and project progress of bank financial products. Once adverse factors are found or judged, if risk factors that may affect the safety of the company’s funds are found in the assessment, corresponding measures will be taken in time to control investment risks.

(3) The Audit Department of the company is responsible for the audit and supervision of the use and custody of low-risk investment and wealth management funds. At the end of each quarter, it shall comprehensively inspect all investment projects of wealth management products, reasonably predict the possible gains and losses of various investments according to the principle of prudence, and report to the Audit Committee;

(4) Independent directors and the board of supervisors have the right to supervise and inspect the use of funds, and can hire professional institutions to audit when necessary. Earnestly implement the articles of association and internal management system, and strictly control risks.

(5) Clarify internal approval procedures. Within the limit, the board of directors of the company authorizes the group financial management center to exercise the investment decision-making power, sign the approval of relevant contract documents, and the group financial management center is responsible for organizing the specific implementation.

The financial products purchased or held by the company are financial products of low-risk financial institutions. The company has fully estimated and calculated the risks and benefits of the entrusted financial products and the future capital demand. The use of corresponding funds will not affect the company’s daily operation and the development of main business, and will help to improve the use efficiency of the company’s idle funds, and the risk is controllable.

3、 Impact on the company

1. The company and its subsidiaries use idle self owned funds to purchase low-risk financial products on the premise of ensuring the company’s daily operation and capital safety, which will not affect the needs of the company’s daily capital turnover and the normal development of the company’s main business.

2. Using its own idle funds to purchase low-risk financial products is conducive to improving the company’s capital use efficiency and income, further improving the company’s overall performance level, which is in line with the interests of all shareholders.

4、 As of March 31, 2022, the company and its subsidiaries have used idle self owned funds to purchase managers

Undue balance of financial products:

Unit: 10000 yuan

Sequence capital source issuer product name product type investment value date maturity date expected receipt No. jineeyi

China China Construction Bank Corporation(601939) stock CCB financial “Huizhong”

1. Self owned Capital Co., Ltd. Feixi (daily application and weekly Redemption) open non breakeven floating 1.012022 / 3 / 152022 / 4 / 6 0.0019 sub branch net worth RMB income type

Financial products

China China Construction Bank Corporation(601939) stock CCB financial “Huizhong”

2. Self owned Capital Co., Ltd. Feixi (daily application and weekly Redemption) open non breakeven floating 1.012022 / 3 / 182022 / 4 / 6 0.0015 sub branch net worth RMB income type

Financial products

The company will disclose its own capital during the reporting period in the periodic report in accordance with the relevant provisions of Shenzhen Stock Exchange

Details of cash management of gold.

5、 Relevant approval procedures and audit opinions

1. Opinions of the board of directors

The 35th meeting of the 5th board of directors of the company deliberated and approved the proposal on continuing to use idle self owned funds to purchase low-risk financial products, and agreed to continue to use no more than RMB 3 billion of idle self owned funds to purchase low-risk financial products. The service life is from the date of deliberation and approval of the company’s 2021 annual general meeting to the date of shareholders’ meeting in 2022. Within the above limit, the funds can be used on a rolling basis, That is, the balance of funds used for investment in low-risk financial products at any one time point shall not exceed RMB 3 billion, and the general meeting of shareholders shall be requested to authorize the group’s financial management center to exercise the investment decision-making power within the limited amount within this period and sign relevant legal documents.

2. Opinions of independent directors

The company’s use of idle self owned funds to purchase low-risk financial products can improve the efficiency of the company’s use of funds and obtain certain investment income. This matter is based on the premise of ensuring the daily operation of the company and does not affect the daily working capital turnover needs of the company and the normal development of its main business. The voting procedure of the company on using idle self owned funds to purchase low-risk financial products is legal and compliant, there is no damage to the interests of shareholders, and the company has formulated strict risk control measures. Therefore, we unanimously agree that from the date of deliberation and approval of the 2021 annual general meeting to the date of the 2022 annual general meeting, the company will continue to use its own idle funds of no more than 3 billion yuan to purchase low-risk financial products.

3. The matter still needs to be submitted to the 2021 annual general meeting of shareholders for deliberation.

6、 Documents for future reference

1. Resolutions of the 35th meeting of the 5th board of directors of the company;

2. Resolutions of the 13th meeting of the 5th board of supervisors of the company;

3. Special instructions and independent opinions of independent directors on matters related to the 35th meeting of the Fifth Board of directors of the company.

It is hereby announced!

Beijing Dabeinong Technology Group Co.Ltd(002385) board of directors April 22, 2022

- Advertisment -